Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Active, not recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

active_not_recruiting375%
recruiting125%

Recent Activity

4 active trials
Showing 4 of 4
recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778
active_not_recruitingphase_2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

NCT06101342
active_not_recruitingphase_2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329
active_not_recruitingphase_2

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

NCT06513312

Clinical Trials (4)

Showing 4 of 4 trials
NCT07473778

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Recruiting
NCT06101342Phase 2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Active Not Recruiting
NCT06101329Phase 2

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Active Not Recruiting
NCT06513312Phase 2

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4